Date: 2011-04-11
Type of information: Grant
Company: Scil Proteins (Germany)
Investors: Investitionsbank Sachsen Anhalt (Germany)
Amount: €700K
Funding type: grant
Planned used: Scil Proteins has received an award of public funding to further establish methods for the combination of Affilin®therapeutics with biological effectors. The Investitionsbank Sachsen Anhalt has provided the Company with €700K to fund relevant in-house research projects. Scil Proteins’ Affilin®therapeutics are so called scaffold proteins derived from the human serum protein Ubiquitin. Affilin®molecules are high affinity binders with excellent target specificity. The Affilin®platform has successfully delivered target specific molecules, which have subsequently shown activity in animal models, within only a few months. Scil Proteins intends to advance into clinical development two Affilin®therapeutic candidates targeting cancer indications.
Others:
Therapeutic area: Cancer - Oncology